Safety Study of Quadrivalent Influenza Virus Vaccine in Healthy People Aged 3 Years and Older

Beijing Chaoyang District Centre for Disease Control and Prevention

Status and phase

Completed

Phase 1

Conditions

Quadrivalent Influenza Virus Vaccine

Treatments

Biological: One dose of Quadrivalent Influenza Virus Vaccine

Study type

Interventional

Funder types

Other

Identifiers

NCT02708173

cycdc2015-5

Details and patient eligibility

About

This study evaluates the safety of Quadrivalent Influenza Virus Vaccine in Healthy People Aged years 3 to 60.40 Subjects will be equally divided into 2 groups,including 3-17 years old and 18-60 years old.Adult group first receive one dose of Quadrivalent Influenza Virus Vaccine.Then minors group also receive one dose of Quadrivalent Influenza Virus Vaccine after 7 days.

Enrollment

40 patients

Sex

All

Ages

3 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

healthy subjects more than 3 years old, and the subjects can be informed consent, and sign the informed consent.
the subjects and his guardians can obey the demands of the scheme .
Axillary temperature less than 37℃

Exclusion criteria

The people who has a vaccine allergies, or who allergic to any kind of composition in experimental vaccine, such as eggs,ovalbumin etc.
The people who has serious side effects to vaccine, such as allergy,urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain.
the subject who has symptoms of acute infection within a week.
Autoimmune diseases or Immune function defect, people has immunosuppressive therapy, cytotoxic treatment or inhaled corticosteroids in the past 6 months.
People has congenital malformations, developmental disorder or serious chronic diseases( such as Down's syndrome, diabetes, Sickle cell anemia or nerve system disease)
People has asthma Unstable that need emergency treatment, hospitalization, intubation, oral or intravenous corticosteroid in the past 2 years.
Diagnosed abnormal coagulation(Lack of clotting factors,Clotting disorders,Platelet abnormality) or significant bruising or coagulopathy
people has history or family history of convulsions, seizures, encephalopathy and psychiatric.
alienia, functional asplenia, and alienia or splenectomy in any situation.
Serious neurological disorders such as Green Barry syndrome.
people who has received blood products or immunoglobulin products in the past one months.
people who has received other study drug in the past one month.
people who received live attenuated vaccine, subunit vaccine or inactivated vaccine.
people who has received allergy treatment in in the past 14 days.
People who is on anti-TB treatment.
People whose axillary temperature is more than 37℃ before the vaccination.
People who is pregnant.
Any factors unsuitable for clinical trail according to the researchers.